Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice
Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)
DOI: 10.1128/aac.00281-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Hilliard L Kutscher und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at…. Hauptthemen laut MEDLINE: Chitosan, Mycobacterium tuberculosis, Nanoparticles, beta-Glucans. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Prolonged daily tuberculosis therapy contributes to toxicity, poor adherence, and drug resistance. We developed rifampin (RIF)-loaded β-glucan-chitosan-poly (lactic co-glycolic) acid nanoparticles (β-C-P nanoparticles) for weekly pulmonary delivery and evaluated a hybrid dosing regimen in a BALB/c Mycobacterium tuberculosis model. Weekly instilled RIF loaded 20% β-C-P nanoparticles combined with daily oral isoniazid (INH) and pyrazinamide (PZA) reduced lung and spleen bacterial burdens comparable to oral daily standard of care (RIF, INH, PZA) and were well tolerated, demonstrating preserved efficacy with reduced RIF dosing frequency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.
- Institute for Lasers, Photonics and Biophotonics, The State University of New York at Buffalo, Buffalo, New York, USA.
- Department of Anesthesiology, The State University of New York at Buffalo, Buffalo, New York, USA.
- Adult and Pediatric Infectious Disease, The State University of New York at Buffalo, Buffalo, New York, USA.
ORCID-Profile: Patrick Kenney, Jessica L Reynolds
Förderung
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Kutscher, H. L., Tamblin, M., Kenney, P., & Reynolds, J. L. (2026). Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.00281-26
Vancouver
Kutscher HL, Tamblin M, Kenney P, Reynolds JL. Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.00281-26
BibTeX
@article{Kutscher2026,
author = {Kutscher, Hilliard L and Tamblin, Maria and Kenney, Patrick and Reynolds, Jessica L},
title = {Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {6},
doi = {10.1128/aac.00281-26}
}
EUVIMED